Amplia uncovers new clue in pancreatic cancer drug trial
Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.
We haven't written up this one. The Age has the full story — the link below goes straight to it.